• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session

    12/29/22 1:14:27 PM ET
    $AFRM
    $BBIO
    $BXRX
    $BYND
    Finance: Consumer Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFRM alert in real time by email

    Gainers

    • Hoth Therapeutics, Inc. (NASDAQ:HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001.
    • Quotient Limited (NASDAQ:QTNT) shares jumped 124% to $0.5382 after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market.
    • Baudax Bio, Inc. (NASDAQ:BXRX) climbed 65.8% to $3.8150 after gaining over 5% on Wednesday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery.
    • Palisade Bio, Inc. (NASDAQ:PALI) gained 52% to $2.76. Palisade Bio recently provided an update on its U.S. Phase 2 study evaluating LB1148 for the reduction in intra-abdominal adhesions in subjects following elective bowel resection.
    • Nuwellis, Inc. (NASDAQ:NUWE) shares climbed 40.5% to $12.88. Nuwellis announced an exclusive U.S. license and distribution agreement for SeaStar Medical Holding’s Selective Cytopheretic Device (SCD) for acute kidney injury (AKI) in children.
    • Motorsport Games Inc. (NASDAQ:MSGM) gained 29.9% to $3.3512.
    • Avalon GloboCare Corp. (NASDAQ:ALBT) jumped 24% to $0.4903.
    • Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) gained 23.3% to $1.4667. Quoin Pharmaceuticals recently announced dosing of first patient in clinical trial in Netherton Syndrome.
    • T Stamp Inc. (NASDAQ:IDAI) gained 22.8% to $0.5701.
    • Freight Technologies, Inc. (NASDAQ:FRGT) gained 22.2% to $0.2750 after the company announced it now supports cross-border logistics requirements for a global electric-electronic equipment company.
    • ASAP, Inc. (NASDAQ:ASAP) gained 22.2% to $0.3987. Aqua Metals 10% owner Kanen Wealth Management LLC acquired a total of 283,250 shares at an average price of $0.71.
    • Taylor Devices, Inc. (NASDAQ:TAYD) jumped 22.1% to $13.30 after the company posted a rise in quarterly earnings.
    • REE Automotive Ltd. (NYSE:REE) surged 21.4% to $0.37.
    • Scilex Holding Company (NASDAQ:SCLX) gained 20.3% to $4.20.
    • Kala Pharmaceuticals, Inc. (NASDAQ:KALA) rose 19.3% to $14.89. Kala Pharmaceuticals shares jumped 218% on Wednesday after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.
    • TG Therapeutics, Inc. (NASDAQ:TGTX) rose 19% to $10.07. TG Therapeutics shares gained 8% on Wednesday following FDA approval of ublituximab.
    • Pingtan Marine Enterprise Ltd. (NASDAQ:PME) gained 17.7% to $0.40.
    • SeqLL Inc. (NASDAQ:SQL) jumped 17.3% to $0.3045.
    • BridgeBio Pharma, Inc. (NASDAQ:BBIO) rose 16.5% to $7.85.
    • Niu Technologies (NASDAQ:NIU) jumped 16.3% to $5.43.
    • Nogin, Inc. (NASDAQ:NOGN) gained 16.2% to $0.7875.
    • Carvana Co. (NYSE:CVNA) rose 16.2% to $4.45.
    • Neptune Wellness Solutions Inc. (NASDAQ:NEPT) gained 16% to $0.33.
    • Relativity Acquisition Corp. (NASDAQ:RACY) gained 15.5% to $11.52.
    • OPKO Health, Inc. (NASDAQ:OPK) gained 14.7% to $1.2050.
    • Coherus BioSciences, Inc. (NASDAQ:CHRS) rose 14.6% to $7.14.
    • Novavax, Inc. (NASDAQ:NVAX) surged 14.4% to $10.37.
    • Hyzon Motors Inc. (NASDAQ:HYZN) shares rose 14.3% to $1.60 after the company announced it entered into an equity capital contribution agreement last week with Chevron New Energies, a division of Chevron’s U.S. business, and Raven SR.
    • Ucommune International Ltd (NASDAQ:UK) surged 14.3% to $1.52.
    • ProKidney Corp. (NASDAQ:PROK) jumped 14% to $6.24.
    • Polestar Automotive Holding UK PLC (NASDAQ:PSNY) gained 13.3% to $5.39.
    • OpGen, Inc. (NASDAQ:OPGN) gained 13.1% to $0.1436.
    • Beyond Meat, Inc. (NASDAQ:BYND) jumped 13% to $12.81.
    • Helbiz, Inc. (NASDAQ:HLBZ) rose 12.6% to $0.1286 after dropping around 9% on Wednesday.
    • Symbotic Inc. (NASDAQ:SYM) gained 12.6% to $12.10.
    • iQIYI, Inc. (NASDAQ:IQ) gained 12.4% to $4.9906.
    • iClick Interactive Asia Group Limited (NASDAQ:ICLK) gained 12.2% to $4.24. iClick Interactive Asia announced a $5 million share repurchase program from January 1, 2023 to December 31, 2023.
    • Sorrento Therapeutics, Inc. (NASDAQ:SRNE) gained 11.4% to $0.8589.
    • Desktop Metal, Inc. (NYSE:DM) gained 11.1% to $1.3105.
    • Matterport, Inc. (NASDAQ:MTTR) jumped 9.9% to $2.65.
    • Elys Game Technology, Corp. (NASDAQ:ELYS) rose 9.4% to $0.2843 after dropping around 30% on Wednesday. Elys Game Technology and Cloakbook were recently granted a license to commence sportsbook operations in Washington, D.C.
    • HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) rose 9.4% to $3.8599 after dropping 18% on Wednesday. HTG Molecular Diagnostics recently announced the closing of a $10 million offering.
    • Mullen Automotive, Inc. (NASDAQ:MULN) rose 9.1% to $0.2314. Mullen Automotive recently announced its I-GO Commercial Urban Delivery EV has arrived Europe.
    • Tesla, Inc. (NASDAQ:TSLA) gained 8.6% to $122.42. The move appears to be driven by positive commentary from CEO Elon Musk and analysts at Morgan Stanley.
    • Smart for Life, Inc. (NASDAQ:SMFL) rose 8.5% to $0.2563. Smart For Life recently announced the launch of Greens First Protein Bars.
    • Affirm Holdings, Inc. (NASDAQ:AFRM) jumped 8.5% to $9.80.
    • Cooper-Standard Holdings Inc. (NYSE:CPS) gained 8.2% to $8.15.
    • Esports Entertainment Group, Inc. (NASDAQ:GMBL) gained 7% to $0.0845 after declining over 10% on Wednesday. Esports Entertainment Group recently named Alex Igelman as Chief Executive Officer.


    Losers

    • F-star Therapeutics, Inc. (NASDAQ:FSTX) shares fell 36.9% to $4.33. The
    • Committee on Foreign Investment issued an interim order preventing closing of pending merger with Invox Pharma Limited, preventing the consummation of the transactions pursuant to the merger agreement citing unresolved national security risks.
    • Jasper Therapeutics, Inc. (NASDAQ:JSPR) dropped 21.1% to $0.4650.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) declined 18.9% to $0.1940.
    • Shineco, Inc. (NASDAQ:SISI) fell 18.6% to $1.70.
    • Titan Medical Inc. (NASDAQ:TMDI) dropped 17.5% to $0.6101. Titan Medical announced receipt of Nasdaq listing determination regarding delisting.
    • Onion Global Limited (NYSE:OG) declined 17.2% to $0.24.
    • MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) fell 15% to $5.10. MEDIROM Healthcare recently posted H1 sales of $23.19 million.
    • Cal-Maine Foods, Inc. (NASDAQ:CALM) fell 14.8% to $52.98. Cal-Maine Foods reported downbeat earnings for its second quarter, while sales topped expectations.
    • Visionary Education Technology Holdings Group Inc. (NASDAQ:VEDU) dropped 13.6% to $0.4034.
    • Gaotu Techedu Inc. (NASDAQ:GOTU) fell 8.3% to $2.5901 after dropping 14% on Wednesday.
    • Minerva Surgical, Inc. (NASDAQ:UTRS) fell 7.4% to $0.2501. Minerva Surgical shares climbed 66% on Wednesday after the company announced a $30 million private placement of common stock led by Accelmed Partners.
    • Rail Vision Ltd. (NASDAQ:RVSN) dropped 7% to $1.19. Rail Vision recently posted a Q3 loss of $0.17 per share.

    Also Check This Out Ethereum Edges Lower But Remains Above This Key Level; BitDAO Emerges As Top Gainer

    Get the next $AFRM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFRM
    $BBIO
    $BXRX
    $BYND

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Affirm Holdings Inc.
    $AFRM
    2/20/2026$55.00Neutral
    Robert W. Baird
    Polestar Automotive Holding UK PLC
    $PSNY
    2/19/2026Neutral → Underweight
    Cantor Fitzgerald
    Symbotic Inc.
    $SYM
    2/19/2026$70.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    Affirm Holdings Inc.
    $AFRM
    2/3/2026$76.00Equal-Weight → Overweight
    Morgan Stanley
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    BridgeBio Pharma Inc.
    $BBIO
    1/28/2026$157.00Overweight
    Barclays
    More analyst ratings

    $AFRM
    $BBIO
    $BXRX
    $BYND
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AFRM
    $BBIO
    $BXRX
    $BYND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

    REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time To access the conference call, please pre-register

    3/2/26 9:30:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Announces Participation in Two Upcoming Investor Conferences

    Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows: TD Cowen 46th Annual Health Care ConferenceDate/time: March 2, 2026 at 3:10 PM ESTLocation: Boston Mariott Copley Place, Boston, MAFormat: In-person presentation & investor meetingsWebcast link: Register here Investors registered to attend the conference who wish t

    3/2/26 9:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

    – Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock– – Cash received supports Precision's expected cash runway through 2028 and strategic focus on in vivo gene editing pipeline – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the achievement of a clinical milestone under its license agreement with TG Therapeutics, Inc. (NASDAQ:TGTX). The milestone payment for azercabtagene zapreleucel (azer-cel) was triggered by progress of a Phase 1 clinical trial of azer-cel in progressive for

    3/2/26 7:01:00 AM ET
    $DTIL
    $TGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AFRM
    $BBIO
    $BXRX
    $BYND
    SEC Filings

    View All

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CapForce Inc. (0001293818) (Filer)

    2/27/26 5:29:02 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form 10-K filed by TG Therapeutics Inc.

    10-K - TG THERAPEUTICS, INC. (0001001316) (Filer)

    2/27/26 5:05:11 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by OPKO Health Inc.

    10-K - OPKO HEALTH, INC. (0000944809) (Filer)

    2/26/26 4:10:02 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFRM
    $BBIO
    $BXRX
    $BYND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Robert W. Baird initiated coverage on Affirm with a new price target

    Robert W. Baird initiated coverage of Affirm with a rating of Neutral and set a new price target of $55.00

    2/20/26 8:23:24 AM ET
    $AFRM
    Finance: Consumer Services
    Finance

    Polestar Automotive Holding UK PLC downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Polestar Automotive Holding UK PLC from Neutral to Underweight

    2/19/26 7:50:28 AM ET
    $PSNY
    Auto Manufacturing
    Industrials

    $AFRM
    $BBIO
    $BXRX
    $BYND
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Delta John bought $13,020 worth of shares (5,000 units at $2.60), increasing direct ownership by 71% to 12,000 units (SEC Form 4)

    4 - Motorsport Games Inc. (0001821175) (Issuer)

    12/12/25 5:31:22 PM ET
    $MSGM
    Computer Software: Prepackaged Software
    Technology

    $AFRM
    $BBIO
    $BXRX
    $BYND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Mcdonald David

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    3/2/26 4:08:18 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Wilson-Thompson Kathleen exercised 40,000 shares at a strike of $14.99 and sold $10,692,814 worth of shares (25,731 units at $415.56), increasing direct ownership by 264% to 19,669 units (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    2/27/26 7:00:21 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Large owner Zoi Mike sold $86,951 worth of shares (24,024 units at $3.62) (SEC Form 4)

    4 - Motorsport Games Inc. (0001821175) (Issuer)

    2/27/26 6:23:34 PM ET
    $MSGM
    Computer Software: Prepackaged Software
    Technology

    $AFRM
    $BBIO
    $BXRX
    $BYND
    Financials

    Live finance-specific insights

    View All

    Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

    REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time To access the conference call, please pre-register

    3/2/26 9:30:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

    MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX's MSTAR technology platform with Regeneron's proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront

    2/26/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AFRM
    $BBIO
    $BXRX
    $BYND
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Polestar starts largest model offensive in its history: four new cars in three years

    Polestar 5 to start deliveries in summer, followed by a new variant of Polestar 4 in Q4 of 2026 Completely new successor of the iconic Polestar 2 in 2027 and compact SUV Polestar 7 in 2028 Michael Lohscheller, Polestar CEO: "Polestar continues to challenge the automotive industry, now by entering fast-growing and high value segments in record speed." Polestar (NASDAQ:PSNY) today announced the largest model offensive in its history, with four new cars planned in the next three years. The Company also announced that with a disciplined approach, in 2026 it expects low double-digit volume growth and a continued retail network expansion of 30%. This press release features multimedia.

    2/18/26 6:00:00 AM ET
    $PSNY
    Auto Manufacturing
    Industrials

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AFRM
    $BBIO
    $BXRX
    $BYND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by iClick Interactive Asia Group Limited

    SC 13D/A - iClick Interactive Asia Group Ltd (0001697818) (Subject)

    12/11/24 7:11:44 AM ET
    $ICLK
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by MEDIROM Healthcare Technologies Inc.

    SC 13G - Medirom Healthcare Technologies Inc. (0001819704) (Subject)

    12/10/24 7:38:12 AM ET
    $MRM
    Other Consumer Services
    Consumer Discretionary